XBiotech trims clinical activity, repays $10M loan; $152.9M cash, 12-month runway

XBiotech Inc. (NASDAQ: XBIT) - Q2 2025 brief

What's happening inside: management cut clinical activity and operating costs in H1 2025, repaid a $10.0 million related-party convertible loan, and recognized significant non‑cash share‑based compensation tied to executive awards. The company remains pre‑revenue and is funding R&D from cash on hand; management states cash is sufficient for at least 12 months.

Key facts & metrics (as reported, in thousands unless noted)
- Cash and cash equivalents: $152,938 (June 30, 2025) (was $172,677 at 12/31/24)
- Total assets: $178,682; Total liabilities: $5,618; Shareholders' equity: $173,064
- Accumulated deficit: (103,477)
- Shares outstanding: 30,487,731
- Net loss - three months ended June 30, 2025: (1,756); six months: (12,640)
- Net loss per share - basic & diluted: (0.06) (Q2); (0.41) (six months)
- Total operating expenses - three months: 6,336 (vs 14,966 prior year); six months: 19,886 (vs 25,819 prior year)
- Research & development: three months: 5,336 (vs 12,984 PY); six months: 16,954 (vs 22,809 PY)
- General & administrative: three months: 1,000 (vs 1,982 PY); six months: 2,932 (vs 3,010 PY)
- Other income (helps offset losses): three months: 4,608 (includes foreign exchange gain 3,081; interest income 1,530); six months: 7,303 (foreign exchange gain 3,365; interest income 3,034)
- Cash flow - six months: operating activities used (12,709); investing used (145); financing used (10,250) - net change (19,739)
- Stock options outstanding: 5,352,681 (total exercisable ~5.4M); weighted-average exercise price $7.80; unrecognized compensation ~$98 to be expensed over ~2.27 years

Positive aspects of the income statement & balance sheet
- Operating spend declined materially vs prior year (R&D down sharply: Q2 R&D $5.3M vs $13.0M a year earlier) - immediate cash burn reduced.
- Strong non‑operating offsets in H1 2025: foreign exchange gains ($3.1M Q2 / $3.4M H1) and interest income ($1.53M Q2 / $3.03M H1) materially reduce reported net loss.
- Balance sheet: low reported liabilities ($5,618) after full repayment of the $10.0M related‑party convertible loan (improves short‑term leverage and removes conversion overhang).
- Cash position ($152.9M) gives management runway and the company explicitly states sufficiency for at least 12 months.

Negative aspects / risks evident from the income statement
- Still unprofitable: six‑month net loss $(12,640) and accumulated deficit $(103,477); the company expects no revenue in 2025.
- R&D decline driven by lack of active trials - while that lowers near‑term spend, it may delay clinical progress and push out value‑creating milestones.
- Large non‑cash share‑based compensation in H1 2025 ($3,436) - largely from immediate‑vesting options to the CEO - increases operating expense and creates dilution risk (5.35M options outstanding).
- Cash declined ~$19.7M in six months; if clinical activity restarts or spending increases, runway will shorten unless the company reduces spend or raises capital.
- Foreign exchange gains helped results this period but are volatile and not recurring revenue.

What to watch next (concise)
- Restart or initiation of clinical trials and related timing/costs (will drive R&D spend and potential value creation).
- Cash burn trajectory vs guidance and any financing or collaboration deals; management cites >12 months runway but that depends on program activity.
- Any milestone or revenue from the Janssen transaction (none earned as of June 30, 2025).
- Dilution from options and future financings; governance questions tied to large immediate‑vesting executive awards.

Bottom line: XBiotech (NASDAQ: XBIT) entered H2 2025 with a healthier liability profile after repaying a related‑party loan and with a meaningful cash balance that management says covers the next 12 months. However, it remains a pre‑revenue, loss‑making biotech where future valuation hinges on clinical progress, timing of trial activity (currently reduced), and whether the company can maintain runway without dilutive financing.